diazoxide has been researched along with Glycogen Storage Disease Type I in 8 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Excerpt | Relevance | Reference |
---|---|---|
"Two originally prepubertal girls suffering from glycogen storage disease type Ia and short stature were treated with low-dose diazoxide (3-4." | 7.69 | Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth. ( Mullis, PE; Nuoffer, JM; Wiesmann, UN, 1997) |
"Two originally prepubertal girls suffering from glycogen storage disease type Ia and short stature were treated with low-dose diazoxide (3-4." | 3.69 | Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth. ( Mullis, PE; Nuoffer, JM; Wiesmann, UN, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (87.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lyen, KR | 1 |
Chrousos, GP | 1 |
Wachlicht-Rodbard, H | 1 |
Adams, AJ | 1 |
Roth, J | 1 |
Cornblath, M | 1 |
Nuoffer, JM | 1 |
Mullis, PE | 1 |
Wiesmann, UN | 1 |
Spahr, RC | 1 |
Gardoni, L | 1 |
Giranzani, F | 1 |
Spergel, G | 1 |
Bleicher, SJ | 1 |
Rennert, OM | 1 |
Mukhopadhyay, D | 1 |
2 reviews available for diazoxide and Glycogen Storage Disease Type I
Article | Year |
---|---|
Hypoglycaemia in infancy and childhood.
Topics: Blood Glucose; Child; Child, Preschool; Diazoxide; Fasting; Glycogen Storage Disease Type I; Humans; | 1984 |
The hepatic glycogenoses.
Topics: Biopsy; Child; Chlorothiazide; Diazoxide; Female; Glucosidases; Glucosyltransferases; Glycogen Stora | 1971 |
6 other studies available for diazoxide and Glycogen Storage Disease Type I
Article | Year |
---|---|
Increased 125I-insulin receptor binding to erythrocytes of hypoglycemic infants and children.
Topics: Adolescent; Adult; Blood Glucose; Child, Preschool; Diazoxide; Erythrocytes; Female; Glycogen Storag | 1981 |
Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth.
Topics: Acidosis, Lactic; Blood Glucose; Child; Child, Preschool; Diazoxide; Female; Food; Glycogen Storage | 1997 |
Von Gierke's disease: a review.
Topics: Allopurinol; Bicarbonates; Blood Glucose; Diazoxide; Gluconeogenesis; Glucose-6-Phosphatase; Glycoge | 1976 |
[Description of a case of type I glycogenosis treated with diazoxide].
Topics: Diazoxide; Glycogen Storage Disease Type I; Humans; Hypoglycemia; Infant; Liver; Male; Seizures | 1978 |
Effects of diazoxide administration on plasma glucose, insulin, and lipids in Von Gierke's disease.
Topics: Antihypertensive Agents; Child; Diazoxide; Drug Eruptions; Drug Hypersensitivity; Glucose Tolerance | 1966 |
Diazoxide in von Gierke's disease.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Child; Diazoxide; Dogs; Galactose; G | 1968 |